Drug Boom; Market Outpaces Growth of Overall World Pharmaceutical Sales ARLINGTON, Va., May 31 /PRNewswire/ -- Friedman, Billings, Ramsey & Co., Inc., a subsidiary of Friedman, Billings, Ramsey Group, Inc. (NYSE: FBR), today identified 12 mid- and small-capitalization companies that are expected to benefit from trends that are driving an increase in the demand for central nervous system drugs, including advances in biotechnology and health problems faced by an aging population. The 48-page report by Equity Analyst Jesse Schulman, Ph.D, identifies the $48.4 billion market for pharmaceuticals that treat conditions that afflict the central nervous system (CNS) including strokes, schizophrenia, multiple sclerosis, and depression. Among the factors driving demand are the lack of good treatments for many CNS disorders, such as Alzheimer's disease, which leaves the market wide open for new and more effective drugs, and the aging Baby Boom population who face increasing risk of age-related CNS disorders, such as stroke. "Central nervous system drug discovery and development is an attractive field for investors," said Dr. Schulman. "The coming years are likely to bring important new therapies into the marketplace from which far-sighted investors can benefit," he said. Mid- and small-capitalization companies have the most to gain from CNS drug discovery and development. Although several major pharmaceutical companies have extensive and successful franchises in CNS therapeutics, many find their research establishment unable to create new drugs at the rate needed to maintain acceptable growth. They are therefore forced to outsource to small biotechnology companies. The report is the first in a series of in-depth research reports from FBR's expanding London office. The 12 companies covered in this report are H Lundbeck A/S (LUN DC); Elan Corporation, Plc (NYSE: ELN) (ELA LN); Shire Pharmaceuticals Group Plc (SHP LN); Vernalis Group Plc (VER LN) (Nasdaq: VNGPF); Sanochemia Pharmazeutika AG (SAC NM); NeuroSearch A/S (NRSH DC); CeNeS Pharmaceuticals Plc (CEN LN); ReNeuron Limited (REN LN); Genset SA (GNST FP); deCODE genetics, Inc. (Nasdaq: DCGN); NicOx SA (NICO FP); and Oxford BioMedica Plc (OXB LN). Friedman, Billings, Ramsey Group, Inc. (NYSE: FBR), the parent company of Friedman, Billings, Ramsey & Co., Inc., is a financial holding company for investment banking, institutional brokerage, specialized asset management, and banking products and services. FBR provides capital and financial expertise throughout a company's lifecycle and affords investors access to a range of proprietary financial products and services. Headquartered in the Washington metropolitan area, FBR has offices in Arlington and Reston, Va., Bethesda, Md., Boston, Charlotte, Chicago, Cleveland, Dallas, Irvine, Ca., New York City, Portland, Seattle, London, and Vienna. Bank products and services are offered by FBR National Bank & Trust, member FDIC and an Equal Housing Lender. For more information, see http://www.fbr.com . This report was prepared by Friedman Billings Ramsey & Co., Inc. (FBR & Co) or one of its affiliates (collectively FBR) based on information available to the public. This report does not represent an offer or a solicitation to buy or sell any security or to pursue any trading strategy. The information included herein is believed to be reliable, but FBR makes no representation as to the accuracy or completeness of such information. The opinions expressed herein are subject to change without notice. Additional information concerning the securities mentioned in this report is available upon request. FBR, and or its affiliates, or their respective officers, directors, and employees (and their family members) may hold long or short positions in the securities discussed herein. Securities discussed are not FDIC insured, guaranteed by any bank, and may lose value. Because of differing client objectives, this report should not be construed as advice designed to meet the particular needs of any investor. Securities denominated in foreign currency typically involve certain currency risks, which may affect the value of the security and the income derived therefrom. In the U.S. this report is approved and distributed by FBR & Co. In the United Kingdom this report is approved and distributed by Friedman Billings Ramsey International Limited (FBRIL), which is regulated by the Securities and Futures Authority (SFA), and is not for distribution to private customers (as defined by the SFA) and no financial instruments discussed herein will be made available to such private customers. No part of this material may be copied or duplicated in any form or by any means, or redistributed without the prior written consent of FBR. Friedman, Billings, Ramsey & Co., Inc. is a member of the National Association of Securities Dealers, CRD number 25027. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X26117570 SOURCE Friedman, Billings, Ramsey & Co., Inc. -0- 05/31/2001 /CONTACT: Michael W. Robinson of Friedman, Billings, Ramsey & Co., Inc., 703-312-1830 or firstname.lastname@example.org/ /Web site: http://www.fbr.com/ (FBR ELN VNGPF DCGN) CO: Friedman, Billings, Ramsey & Co., Inc.; Friedman, Billings, Ramsey Group, Inc.; H Lundbeck A-S; Elan Corporation, Plc; Shire Pharmaceuticals Group Plc; Vernalis Group Plc; Sanochemia Pharmazeutika AG; NeuroSearch A/S; CeNeS Pharmaceuticals Plc; ReNeuron Limited; Genset SA; deCODE genetics, Inc.; NicOx SA; Oxford BioMedica Plc ST: Virginia, England IN: HEA MTC SU: -0- May/31/2001 18:12 GMT
FBR Identifies Companies Set to Gain from Central Nervous System
Press spacebar to pause and continue. Press esc to stop.